RecruitingPhase 2NCT06509984

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Studying Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Centre Hospitalier Universitaire de Nice
Intervention: Apremilast treatment(drug)
Enrollment: 20 enrolled
Eligibility: 6-99 years · All sexes
Timeline: 2024 – 2026

Study locations (4)

CHU de Nice, Nice, France, France
APHP Necker-Enfants-Malades, Paris, France, France
APHP Hôpital Saint-Louis, Paris, France, France
chu de Toulouse, Toulouse, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06509984 on ClinicalTrials.gov

Other trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06073132
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
TWi Biotechnology, Inc.

See all trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form →

← Back to all trials